International Journal of Hematology

, Volume 80, Issue 1, pp 94–96 | Cite as

Treatment of Resistant Thrombotic Thrombocytopenic Purpura with Rituximab and Cyclophosphamide

  • Gideon Y. Stein
  • Aliza Zeidman
  • Zinaida Fradin
  • Meir Varon
  • Amos Cohen
  • Moshe Mittelman


Thrombotic thrombocytopenic purpura (TTP) is an uncommon acquired disease in adults, especially young women, characterized by fever, neurologic manifestations, microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction. Treatment with plasmapheresis has increased the survival rate from 10% to greater than 90%. Still, a subset of patients with resistant TTP fail to respond to plasmapheresis or remain dependent on this procedure.We report such a patient who was successfully treated with rituximab and cyclophosphamide. She has now been disease free for more than 6 months. This novel treatment modality for TTP has been described for only a few patients.A well-controlled clinical trial is warranted to determine the role and place of this therapeutic approach in the management of TTP.

Key words

Thrombotic thrombocytopenic purpura Plasmapheresis ADAMTS-13 Rituximab 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Furlan M, Robles R, Galbusera M, et al. von Willebrand factorcleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578–1584.CrossRefGoogle Scholar
  2. 2.
    Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097–3103.PubMedGoogle Scholar
  3. 3.
    Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura: Canadian Apheresis Study Group. N Engl J Med. 1991;325:393–397.CrossRefPubMedGoogle Scholar
  4. 4.
    Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: clinical experience in 108 patients. N Engl J Med. 1991;325:398–403.CrossRefPubMedGoogle Scholar
  5. 5.
    Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis. 2002;28:385–391.CrossRefPubMedGoogle Scholar
  6. 6.
    Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med. 2003;138:105–108.CrossRefPubMedGoogle Scholar
  7. 7.
    Chemnitz J, Draube A, Scheid C, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002;71:105–108.CrossRefPubMedGoogle Scholar
  8. 8.
    Tsai HM, Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol. 2003;70:183–185.CrossRefPubMedGoogle Scholar
  9. 9.
    Rabkin Y, Fradin Z, Zeidman A, Schwartz A, Cohen A, Mittelman M. Chronic relapsing thrombocytopenic purpura with severe neurological manifestations and full recovery. Int J Hematol. 2000;71:184–187.PubMedGoogle Scholar
  10. 10.
    Dabrow MB, Wilkins JC. Hematologic emergencies: management of hyperleukocytic syndrome, DIC, and thrombotic thrombocytopenic purpura. Postgrad Med. 1993;93:193–194, 197-199, 202.CrossRefPubMedGoogle Scholar
  11. 11.
    Moake JL, Rudy CK, Troll JH, et al. Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine. Am J Hematol. 1985;20:73–79.CrossRefPubMedGoogle Scholar
  12. 12.
    Thompson HW, McCarthy LJ. Thrombotic thrombocytopenic purpura: potential benefit of splenectomy after plasma exchange. Arch Intern Med. 1983;143:2117–2119.CrossRefPubMedGoogle Scholar
  13. 13.
    Van Gool S, Brock P, Van Laer P, Van Damme-Lombaerts R, Proesmans W, Casteels-Van Daele M. Successful treatment of recurrent thrombotic thrombocytopenic purpura with plasmapheresis and vincristine. Eur J Pediatr. 1994;153:517–519.CrossRefPubMedGoogle Scholar
  14. 14.
    Kolodziej M. Case report: high-dose intravenous immunoglobulin as therapy for thrombotic thrombocytopenic purpura. Am J Med Sci. 1993;305:101–102.CrossRefPubMedGoogle Scholar
  15. 15.
    Lee EJ, Kueck B. Rituxan in the treatment of cold agglutinin disease. Blood. 1998;92:3490–3491.PubMedGoogle Scholar
  16. 16.
    Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology. 1999; 52:1701–1704.CrossRefPubMedGoogle Scholar
  17. 17.
    Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti- CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952–957.CrossRefGoogle Scholar
  18. 18.
    Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet. 2002;360:923–924.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  • Gideon Y. Stein
    • 1
  • Aliza Zeidman
    • 1
  • Zinaida Fradin
    • 1
  • Meir Varon
    • 1
  • Amos Cohen
    • 1
  • Moshe Mittelman
    • 1
  1. 1.Department of Internal Medicine B and the Hematology Unit, Rabin Medical Center, Golda-Hasharon CampusPetah Tikva, Tel Aviv University, Sackler School of MedicinePetah TikvaIsrael

Personalised recommendations